246 related articles for article (PubMed ID: 26667485)
1. A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
Lee JY; Sun JM; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Ku BM; Koh J; Bae YH; Lee SH; Ahn JS; Park K; Ahn MJ
Clin Cancer Res; 2016 May; 22(9):2139-45. PubMed ID: 26667485
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
Kim SH; Shim HS; Cho J; Jeong JH; Kim SM; Hong YK; Sung JH; Ha SJ; Kim HR; Chang H; Kim JH; Tania C; Cho BC
Lung Cancer; 2013 Mar; 79(3):270-5. PubMed ID: 23261229
[TBL] [Abstract][Full Text] [Related]
3. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM
Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849
[TBL] [Abstract][Full Text] [Related]
4. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R
Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
[TBL] [Abstract][Full Text] [Related]
6. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N
J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963
[TBL] [Abstract][Full Text] [Related]
7. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Schuler M; Yang JC; Park K; Kim JH; Bennouna J; Chen YM; Chouaid C; De Marinis F; Feng JF; Grossi F; Kim DW; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand VK; Planchard D;
Ann Oncol; 2016 Mar; 27(3):417-23. PubMed ID: 26646759
[TBL] [Abstract][Full Text] [Related]
8. Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.
Yu S; Zhang B; Xiang C; Shu Y; Wu H; Huang X; Yu Q; Yin Y; Guo R
Clin Lung Cancer; 2015 Mar; 16(2):121-7. PubMed ID: 25450874
[TBL] [Abstract][Full Text] [Related]
9. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
[TBL] [Abstract][Full Text] [Related]
11. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
[TBL] [Abstract][Full Text] [Related]
12. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K
Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Burotto M; Manasanch EE; Wilkerson J; Fojo T
Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
[TBL] [Abstract][Full Text] [Related]
14. A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer.
Felip E; Ranson M; Cedrés S; Dean E; Brewster M; Martínez P; McNally V; Ross G; Galdermans D
Clin Lung Cancer; 2012 Nov; 13(6):432-41. PubMed ID: 22609229
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
16. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
Yoshimura N; Okishio K; Mitsuoka S; Kimura T; Kawaguchi T; Kobayashi M; Hirashima T; Daga H; Takeda K; Hirata K; Kudoh S
J Thorac Oncol; 2013 Jan; 8(1):96-101. PubMed ID: 23207920
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
Ninomiya T; Nogami N; Kozuki T; Harada D; Kubo T; Ohashi K; Kuyama S; Kudo K; Bessho A; Fukamatsu N; Fujimoto N; Aoe K; Shibayama T; Sugimoto K; Takigawa N; Hotta K; Kiura K
Lung Cancer; 2018 Jan; 115():103-108. PubMed ID: 29290249
[TBL] [Abstract][Full Text] [Related]
18. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
[TBL] [Abstract][Full Text] [Related]
19. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
Lind JS; Dingemans AM; Groen HJ; Thunnissen FB; Bekers O; Heideman DA; Honeywell RJ; Giovannetti E; Peters GJ; Postmus PE; van Suylen RJ; Smit EF
Clin Cancer Res; 2010 Jun; 16(11):3078-87. PubMed ID: 20395213
[TBL] [Abstract][Full Text] [Related]
20. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
Kim HR; Jang JS; Sun JM; Ahn MJ; Kim DW; Jung I; Lee KH; Kim JH; Lee DH; Kim SW; Cho BC
Oncotarget; 2017 Feb; 8(9):15943-15951. PubMed ID: 27823977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
